Esophageal carcinoma

Wednesday, April 22, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. Beneficial subgroups for PD-1 inhibitor plus chemotherapy in first-line treatment of advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.

Medicine (2026) - Meta-Analysis

Key Findings

Across 8 randomized trials with 4702 patients, first-line PD-1 inhibitor plus chemotherapy improved overall survival versus chemotherapy alone (HR 0.68, 95% CI 0.63-0.74).
Progression-free survival and objective response rate also improved (PFS HR 0.62, 95% CI 0.58-0.66; ORR RR 2.03, 95% CI 1.80-2.29), without a reduction in grade 3-5 treatment-related adverse events.
Overall survival improved less in the PD-L1 CPS below 1 subgroup, whereas efficacy remained improved across age, metastatic status, metastatic burden, and liver metastasis subgroups.

📋 Practice Implication: For advanced ESCC, PD-1 inhibitor plus chemotherapy should remain a default first-line backbone for eligible patients, but PD-L1 CPS below 1 should prompt a more cautious expectation of benefit.

2. Neoadjuvant chemotherapy with or without PD-1/PD-L1 inhibitors in resectable esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials.

BMC Gastroenterology (2025) - Meta-Analysis

Key Findings

Adding PD-1/PD-L1 blockade to neoadjuvant chemotherapy increased pathologic complete response (RR 2.66, 95% CI 1.63-4.34) and major pathologic response (RR 1.74, 95% CI 1.02-2.95).
In the phase III survival data included, chemoimmunotherapy improved overall survival (HR 0.48, 95% CI 0.24-0.96) and event-free survival (HR 0.62, 95% CI 0.39-0.99).
Surgery rates and lymph node yield increased with chemoimmunotherapy, but immune-related adverse events were also increased (RR 40.80, 95% CI 5.67-293.37).

📋 Practice Implication: In resectable ESCC, neoadjuvant chemoimmunotherapy is a strong option when the team can manage immune toxicities and wants to maximize pathologic response before surgery.

3. Neoadjuvant Immunochemoradiation Therapy Versus Chemoradiation Therapy in Esophageal Cancer: A Systematic Review and Meta-Analysis of Reconstructed Individual Patient Data.

International Journal of Radiation Oncology, Biology, Physics (2025) - Meta-Analysis

Key Findings

Compared with standard neoadjuvant chemoradiation, immunochemoradiation was associated with longer overall survival (HR 0.714, 95% CI 0.550-0.926), with 3-year overall survival 66.4% versus 57.3%.
Among squamous cell carcinoma cases, pathologic complete response was higher with immunochemoradiation (50% vs 38%, P = 0.040).
Grade 3-4 treatment-related adverse events and postoperative complications were not significantly increased versus standard chemoradiation.

📋 Practice Implication: For resectable disease already headed toward radiation-based neoadjuvant therapy, adding immunotherapy appears to improve efficacy without a clear perioperative safety penalty.

4. Neoadjuvant Chemoradiation Versus Chemotherapy for Esophageal Cancer: A Histology-Stratified Update Meta-Analysis of Randomized Controlled Trials.

Annals of Surgical Oncology (2026) - Meta-Analysis

Key Findings

In squamous cell carcinoma, neoadjuvant chemoradiation increased resection rates (OR 1.94, 95% CI 1.05-3.60) and pathologic complete response (OR 8.78, 95% CI 3.27-23.57) versus chemotherapy alone.
Chemoradiation also reduced local recurrence in squamous tumors (OR 0.58, 95% CI 0.40-0.86) and improved 3-year overall survival (OR 1.51, 95% CI 1.16-1.96).
These long-term advantages were not seen in adenocarcinoma, where overall survival and local recurrence were not improved by chemoradiation versus chemotherapy alone.

📋 Practice Implication: Treatment planning for resectable esophageal cancer should stay histology-specific, with squamous tumors favoring chemoradiation while adenocarcinoma may not gain the same survival advantage.

5. PD-1/PD-L1 inhibitors in advanced, unresectable esophageal squamous-cell carcinoma: A meta-analysis of their effects across patient subgroups.

Critical Reviews in Oncology/Hematology (2025) - Meta-Analysis

Key Findings

PD-1/PD-L1 inhibitors improved overall survival in both first-line chemoimmunotherapy (HR 0.68, 95% CI 0.63-0.74) and second-line monotherapy (HR 0.73, 95% CI 0.66-0.81) for advanced ESCC.
Progression-free survival improved in the first-line setting (HR 0.62, 95% CI 0.58-0.67) but not in second-line therapy (HR 0.89, 95% CI 0.76-1.04).
Overall survival was not improved in PD-L1-negative disease with CPS below 1 and improved most in CPS 10 or higher; current smokers also did not show a significant survival gain.

📋 Practice Implication: When selecting later-line immunotherapy for advanced ESCC, PD-L1 status and clinical context matter more than in first-line use, because survival benefit is uneven and disease control is weaker beyond the frontline.

💡 Summary

Recent evidence in esophageal carcinoma is dominated by esophageal squamous cell carcinoma studies showing that checkpoint inhibitor intensification improves outcomes in both first-line advanced disease and several neoadjuvant settings. Histology-stratified data continue to support chemoradiation over chemotherapy alone for resectable squamous tumors, while biomarker and line-of-therapy analyses suggest benefit is attenuated in PD-L1 CPS below 1 and less robust for progression-free survival in second-line immunotherapy monotherapy.